Evidence map›Paper›PMID 36696567›Full record

ReviewExpert opinion on investigational drugs2023

Immunotherapeutic strategies for treating opioid use disorder and overdose.

Rachel Luba, Suky Martinez, Jermaine Jones, Marco Pravetoni, Sandra D Comer

Open access · greenAbstract readReview
In one paragraph

Review in Expert opinion on investigational drugs, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
3.2field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 11 citations in OpenAlex.

  1. An antifentanyl monoclonal antibody reverses fentanyl-induced apnea in pigs.The Journal of pharmacology and experimental therapeutics · 2025
    Article
  2. Review
  3. Review
  4. Article
  5. Review
  6. No time to lose: the current state of research in rapid-acting psychotherapeutics.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2024
    Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Rachel LubaNew York State Psychiatric Institute/Columbia University Irving Medical Center Division on Substance Use Disorders, New York, NY, USA.ORCID 0000-0003-3404-766X
Suky MartinezNew York State Psychiatric Institute/Columbia University Irving Medical Center Division on Substance Use Disorders, New York, NY, USA.ORCID 0000-0002-4873-8130
Jermaine JonesNew York State Psychiatric Institute/Columbia University Irving Medical Center Division on Substance Use Disorders, New York, NY, USA.ORCID 0000-0003-4476-2800
Marco PravetoniDepartment of Pharmacology, University of Washington, School of Medicine, Department of Psychiatry and Behavioral Sciences, Center for Medication Development for Substance Use Disorders and Overdose, Seattle WA, USA.ORCID 0000-0003-1036-0184
Sandra D ComerNew York State Psychiatric Institute/Columbia University Irving Medical Center Division on Substance Use Disorders, New York, NY, USA.ORCID 0000-0002-8166-548X
Columbia University · USUniversity of Washington · US

Funding

Phase 1a/1b Clinical Trials of Multivalent Opioid Vaccine ComponentsUG3DA047711 · NIDA · NEW YORK STATE PSYCHIATRIC INSTITUTE DBA RESEARCH FOUNDATION FOR MENTAL HYGIENE, INC · PI COMER, SANDRA D, PRAVETONI, MARCO · 2018 to 2019
$9.4M
Translational Clinical Research Fellowship on Substance Use DisordersT32DA007294 · NIDA · COLUMBIA UNIV NEW YORK MORNINGSIDE · PI Frances Rudnick Levin, Diana M Martinez · 1993 to 2026
$9.3M
Translational Research Training on Addictions for Racial/Ethnic MinoritiesR25DA035161 · NIDA · CITY COLLEGE OF NEW YORK · PI DENISE AIMEE HIEN, Lesia Monique Ruglass · 2013 to 2026
$4.4M
NIDA NIH HHS R25 DA035161NIDA NIH HHS T32 DA007294NIDA NIH HHS UG3 DA047711
6 · The paper itself

Abstract

introductionDevelopment and implementation of effective treatments for opioid use disorder (OUD) and prevention of overdose are urgent public health needs. Though existing medications for OUD (MOUD) are effective, barriers to initiation and retention in treatment persist. Therefore, development of novel treatments, especially those may complement existing treatments, is needed. AREAS COVERED: This review provides an overview of vaccines for substance use disorders (SUD) and mechanisms underlying their function and efficacy. Next, we focus on existing preclinical and clinical trials of SUD vaccines. We focus briefly on related strategies before providing an expert opinion on prior, current, and future work on vaccines for OUD. We included published findings from preclinical and clinical trials found on PubMed and ScienceDirect as well as ongoing or initiated trials listed on ClinicalTrials.gov. EXPERT OPINION: The present opioid overdose and OUD crises necessitate urgent development and implementation of effective treatments, especially those that offer protection from overdose and can serve as adjuvants to existing medications. Promising preclinical trial results paired with careful efforts to develop vaccines that account for prior SUD vaccine shortcomings offer hope for current and future clinical trials of opioid vaccines. Clinical advantages of opioid vaccines appear to outnumber disadvantages, which may result in improved treatment options.

Indexed as

BuprenorphineOpioid-Related DisordersVaccinesAnalgesics, OpioidHumansImmunotherapyAnalgesics, OpioidBuprenorphineVaccinesCocainefentanylheroinimmunotherapiesnicotineopioidsopioid use disorderoxycodonesubstance use disordersVaccines

Identifiers

PMID36696567
PMCPMC10035039
OpenAlexW4318170741

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.